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The role of pluripotency gene regulatory network components in
mediating transitions between pluripotent cell states§
Nicola Festuccia, Rodrigo Osorno, Valerie Wilson and Ian Chambers
Available online at www.sciencedirect.comPluripotency is a property that early embryonic cells possess
over a considerable developmental time span. Accordingly,
pluripotent cell lines can be established from the pre-
implantation or post-implantation mouse embryo as embryonic
stem (ES) or epiblast stem (EpiSC) cell lines, respectively.
Maintenance of the pluripotent phenotype depends on the
function of specific transcription factors (TFs) operating within a
pluripotency gene regulatory network (PGRN). As cells move
from an ES cell to an EpiSC state, the PGRN changes with
expression of some TFs reduced (e.g. Nanog) or eliminated
(e.g. Esrrb). Re-expressing such TFs can move cells back to an
earlier developmental identity and is being applied to attempt
establishment of human cell lines with the properties of mouse
ES cells.
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Introduction
The formation of epiblast cells within the inner cell mass
(ICM) of pre-implantation mammalian embryos marks
the establishment of pluripotency [1]. The resulting
pluripotent cells are the cells from which all specialised
cells that make up the developing embryo and indeed all
tissues of the adult organism trace their origins. Despite
the transient requirement for such cells, pluripotency is a
capacity that lasts for several days spanning implantation
and that can be propagated indefinitely in vitro by the§ This is an open-access article distributed under the terms of the
Creative Commons Attribution-NonCommercial-No Derivative Works
License, which permits non-commercial use, distribution, and repro-
duction in any medium, provided the original author and source are
credited.
Current Opinion in Genetics & Development 2013, 23:504–511 establishment of pluripotent cell lines. Although they
share the functional capacity for multilineage differen-
tiation, pluripotent cell lines show differences in their
properties. Not only are there differences between the
growth factor requirements of pluripotent cell lines with
an established pre-implantation (embryonic stem; ES) or
post-implantation (so-called epiblast stem; EpiSC) iden-
tity but these cells also differ in the TFs that impinge
upon the PGRN [2,3]. In this review we discuss recent
insights into the operation of the PGRN with a particular
focus on Nanog. We discuss how changes in the network
can alter cell state as cells move from a pre-implantation
to post-implantation identity and beyond, as well as when
cells are reprogrammed to an ES cell state.
Factors regulating embryonic pluripotency
The ICM of early embryos is characterised by expression of
three fundamental regulators of pluripotency: the TFs
Oct4, Sox2 and Nanog (Figure 1). The requirement of
these factors for specification of pluripotency in vivo and
maintenance in vitro and their expression kinetics during
pre-implantation development have been reviewed
recently [4] and will not be recounted in detail here.
However, it is worth noting that at E3.5 Nanog expression
becomes heterogeneous in the ICM [5]. This is critical to
the choice between maintaining pluripotency or differen-
tiating into primitive endoderm. Cells retaining Nanog
proceed to complete transcriptional and epigenetic reset-
ting including reactivation of the inactive paternally inher-
ited X chromosome in females [6]. A recent study has
shown that in contrast to other pluripotency TFs, Nanog is
initially transcribed in a random mono-allelic manner with
a switch to bi-allelic expression occurring at the late blas-
tocyst stage around E4.25 [7]. Why Nanog expression
should be controlled in this particularly interesting way
rather than by simply increasing the transcription of both
alleles is an interesting question for the future.
Nanog expression is down-regulated in the epiblast
before implantation [8], becoming re-activated in the
posterior post-implantation epiblast [9] (Figure 1).
Subsequently, Nanog and Oct4 become undetectable
when embryos have developed two or 15 somites,
respectively. In contrast, Sox2 expression continues
but becomes restricted to the neuroectoderm and caudal
neural plate. Loss of pluripotency occurs at the onset of
somitogenesis preceding the total elimination of Oct4
[9]. Before this, Nanog expression in the epiblast
becomes restricted at a time when cell fate becomes
regionalized [9,10]. Although the ability to expresswww.sciencedirect.com
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Nanog, Oct4 and Sox2 expression dynamics during murine development. Whereas Oct4 and Sox2 mRNAs are inherited maternally, Nanog mRNA is
first detected in blastomeres of the 8 cell stage embryo [62]. At E3.5 Nanog is expressed heterogeneously in the ICM, with segregation of Nanog
positive and negative cells leading to formation of the epiblast and hypoblast at E4.5. Around implantation Nanog is downregulated before being re-
expressed in the posterior epiblast. Nanog remains regionally expressed but progressively declines until being lost at the onset of somitogenesis. Oct4
and Sox2 also become regionally expressed post-implantation, with Sox2 higher in the anterior epiblast and Oct4 becoming progressively posterior. In
PGCs (that retain Oct4 expression throughout development) Sox2 becomes detectable at neural plate stage, with Nanog upregulated by the 2–3s
stage. Nanog and Sox2 are expressed by PGCs until E12.5 (an E12.5 genital ridge is represented) before becoming undetectable at E15.5 and E14.5 in
males and females respectively. Oct4 expression is also lost at E14.5 as female germ cells enter meiosis but persists longer in male PGCs (E,
embryonic day; s, number of somites).Nanog marks post-implantation epiblast cells as pluripo-
tent, Nanog is strictly dispensable for pluripotency [9].
Despite the fact that cell fate, morphogens and TFs are
regionalized in gastrulating embryos, cells with demon-
strable pluripotency persist throughout the epiblast [9].
Therefore, before somitogenesis, the epiblast exists in a
pre-commitment state, characterized by reduced, but
reversible PGRN activity. Downregulation of Oct4
below a threshold level required to maintain the PGRN
leads to the extinction of pluripotency through chromatin
closure at key regulatory elements, such as those at the
Nanog and Oct4 loci. Following loss of pluripotency, re-
elevating Oct4 expression restores chromatin accessibil-
ity at regulatory elements and can rescue pluripotency for
several days before DNA methylation changes preclude
effective Oct4 action [9].
Relationship to the germline
The pre-implantation PGRN becomes reactivated in
primordial germ cells (PGCs) before epigenetic repro-
gramming occurs. PGC development has recently been
reviewed [11]. Intriguingly, some of the same genes
required to specify pre-implantation pluripotency are
crucial for PGC development. Oct4 is essential to prevent
apoptosis of PGCs after E9.5 [12] and Nanog is required
for PGC development beyond E11.5 [13,14]. The recent
development of protocols to efficiently generate PGCs
from ES cells will enable the contribution of additional
pluripotency factors to germ cell development to be
systematically tested [15]. How the activity of a gene
regulatory network can on the one hand direct robust
pluripotent identity while on the other be associated with
a unipotent cell identity is a tantalising issue. Recently,
the textbook example of reprogramming of unipotentwww.sciencedirect.com PGCs to a pluripotent identity has been achieved using
MEK/GSK3b inhibitors in place of FGF/SCF alongside
co-culture with fibroblasts supplemented with LIF [16].
The precise steps involved in this conversion are not
elucidated but perhaps altering the concentration of a
single pluripotency TF may suffice.
Capturing pluripotency in vitro: ES cells and
EpiSC
Pluripotent cells from the pre-implantation mouse
embryo can be captured in vitro as ES cell lines. These
cells can differentiate into each of the three primary germ
layers and, when introduced into the pre-implantation
embryo, can also colonise the germline. ES cells broadly
maintain the molecular traits of the ICM, including
expression of crucial pluripotency regulators [17] and
the presence of two active X chromosomes in female
cells. Despite this, ES cells differ from ICM cells most
notably by having higher expression of genes involved in
epigenetic silencing [17]. ES cells cultured in LIF/FCS
show heterogeneous expression of several pluripotency
TFs including Nanog, Rex-1, Stella, Klf4 and Tbx3
[4,18]. Nanog protein autorepresses Nanog gene transcrip-
tion [19,20] thereby contributing to heterogeneity [19].
Surprisingly, ES cells with a reduced level of Oct4 do not
exhibit such heterogeneity, instead showing relatively
uniform, high expression of Nanog and other TFs [21].
Post-implantation epiblast cells can also be established in
vitro as EpiSC lines [2,3] but these differ from ES cells by
requiring Activin/FGF rather than LIF/BMP for main-
tenance. EpiSCs can also be obtained by explanting pre-
implantation mouse embryos in Activin/FGF instead of
LIF/BMP [22]. This indicates that environmentalCurrent Opinion in Genetics & Development 2013, 23:504–511
506 Cell reprogrammingsignals determine the cell type captured in vitro, an
observation that extends to reprogramming experiments
[23]. In accordance with a post-implantation identity,
EpiSC lines derived from female embryos have one
inactive X chromosome [24]. EpiSCs are pluripotent, as
demonstrated by their teratocarcinoma forming capacity
and their ability to differentiate in vitro not only into
somatic cells but also into germ cells [23,25]. Despite
this, questions remained about the developmental
relevance of EpiSCs since they lack the efficient capacity
of ES cells to resume development following introduction
into blastocysts [2]. Using an Oct4-DE:GFP reporter that
is predominantly active in the pre-implantation epiblast,
EpiSCs from early post-implantation embryos show
heterogeneous reporter expression with the minor
GFP+ population possessing an increased ability to con-
tribute to chimaeras following blastocyst injection [26]. In
addition, overexpression of E-cadherin in EpiSCs also
increases the proportion of chimaeras following blastocyst
injection [27]. Excitingly, EpiSCs have recently been
shown to participate efficiently in development when
introduced into the appropriate environment of the
post-implantation embryo, before but not following the
loss of embryonic pluripotency [28]. Underscoring the
importance of this finding, ES cells lack this ability [28].
These findings demonstrate that the ability to reveal the
developmental competence of a cell line depends not
only upon the intrinsic state of the cells but also requires a
match between the developmental stage of the ‘captured’
cell line and the host environment: chimaera formation
can occur when functionally equivalent cultured cells and
host tissue are juxtaposed.Figure 2
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implantation transition in vitro
TFs expressed in the Nanog positive epiblast cells of the
ICM, such as Esrrb, Klf4, Klf5, Rex1 and Tbx3 are
undetectable in the E7.5 epiblast [29–32]. The require-
ment for pluripotency TFs during implantation is rela-
tively difficult to study due to the inaccessibility of the
peri-implantation embryo. However, the derivation of
EpiSC by passaging of ES cells in serum free medium
supplemented with Activin/FGF [24] provides a tractable
model for studying the transition in pluripotent states that
occurs at implantation. Several of the pluripotency TFs
downregulated following implantation are also downre-
gulated in EpiSCs [4]. Among the core pluripotency
factors, Oct4 expression is maintained, whereas Sox2
and Nanog expression are reduced [4,24,26]. In ES cells,
Nanog directs transcription of a cohort of regulators of
pre-implantation pluripotency that are differentially
expressed between ES cells and EpiSCs, including Esrrb,
Klf4, Klf5, Rex1 and Tbx3 [33] (Figure 2). Therefore,
these genes may be co-ordinately down-regulated in
response to declining Nanog levels at the peri-implan-
tation stage. Perhaps reduced concentrations of Nanog
and/or Nanog target gene(s) may be required to facilitate
the pre-implantation to post-implantation pluripotency
transition.
Supporting the importance of Nanog downregulation at
implantation, ES cells overexpressing Nanog resist differ-
entiation into EpiSCs, and retain, albeit at reduced levels,
expression of ES cell markers after repeated passaging in
Activin/FGF [4]. Resistance to differentiation is directly (hours)
Esrrb
Klf4
Klf5
Rex1
Tbx3
Tet2
Prdm14
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pplementary information in [33]).
www.sciencedirect.com
The role of Nanog in pluripotent state transitions Festuccia et al. 507correlated with the Nanog level [4], suggesting that high
Nanog concentrations stabilise ES cell pluripotency even
in the presence of differentiation signals such as retinoic
acid, 3-methoxybenzamide or Activin/FGF [4,8].
New studies have identified two basic helix-loop-helix
TFs that operate at this juncture. Tcf15 becomes
expressed in the epiblast just before implantation and
represses Nanog [34]. The second, Tfe3 relocalises from
the nucleus to the cytoplasm during the implantation
transition in vitro and in vivo. Preventing cytoplasmic
relocalisation of Tfe3 blocks the loss of ES cell pluripo-
tency [35].
Interestingly, Wnts have recently been demonstrated to
sustain ES cells in culture when provided alongside LIF
[36]. Although this has been proposed to occur by
blockade of the ES to EpiSC transition, the mechanisms
involved are not fully resolved [37]. Gene repression by
TCF3 appears to play a part and has been proposed to
explain how GSK3b inhibition can promote ES cell self-
renewal [38,39]. Interestingly, the Nanog target gene
Esrrb is amongst the most functionally relevant targets
of GSK3b inhibition [40]. Recently, E-cadherin, which is
physically linked to Wnt signalling via b-catenin, has
been demonstrated to cooperate with LIFR/gp130 for
LIF signalling [41], which could contribute to the Wnt
mediated effect.
Learning from in vitro studies: the stalled
reprogramming of Nanog-null cells.
Relative to the in vitro generation of EpiSC, reprogram-
ming by enforced expression can provide complementary
information on the role of TFs in promoting acquisition of
pluripotency. Nanog is not in the original reprogramming
factor cocktail [42]. However, Nanog is expressed late
during reprogramming [43,44,45] and is required to
complete reprogramming [6]. Nanog/ somatic cells
can be reprogrammed to a state in which they acquire
the morphology and growth factor dependence of ES cells
[6]. However, as they neither activate endogenous plur-
ipotency TF gene transcription, nor silence the repro-
gramming factor transgenes they are not fully
reprogrammed [6]. This is interesting in light of recent
data suggesting that pre-iPS cells may have high Oct4
transgene expression, which is incompatible with self-
renewal of ES/iPS cells [46,47]. Restoring Nanog expres-
sion to partially reprogrammed lines facilitates the tran-
sition to a fully reprogrammed state [6]. This raises the
intriguing possibility that Nanog plays a critical role in
imposing the transcriptional and epigenetic state required
to silence transgene expression. Recent evidence pro-
vides some insight into the mechanisms by which Nanog
may achieve reprogramming. Forced expression of the
direct Nanog target gene Esrrb, in Nanog/ pre-iPS cells
triggers complete reprogramming when combined with
5’Azacytidine treatment [33]. Furthermore, Nanogwww.sciencedirect.com interacts with Tet1 ([48] and our unpublished infor-
mation) and induces Tet2 expression ([33,48] and
Figure 2). Concomitant elevation of Tet1 and Nanog
in Nanog / pre-iPSCs cooperatively enhances iPS cell
generation [48]. The overlap in chromatin binding
between Tet1 and Nanog suggests that Nanog may
bring Tet1 to the methylated regulatory regions of key
pluripotency genes, thereby triggering hydroxymethyla-
tion, potential subsequent demethylation and activation
of the PGRN. Therefore, Nanog might trigger com-
pletion of reprogramming both by directing transcription
of key pluripotency regulators and by targeting silent
PGRN loci for epigenetic reawakening.
Learning from in vitro studies: reprogramming
EpiSCs to ES cells
The transition of EpiSCs to an ES-like state provides an
additional approach to reveal the molecular requirements
for attaining pre-implantation pluripotency. Overexpres-
sion of Nanog together with a change in culture con-
ditions can drive reprogramming of EpiSC to ES-like
cells [4,6]. This conversion is accompanied by acquisition
of an ES cell gene expression profile and is marked by
reactivation of the inactive X chromosome in female lines
[6]. Although similar reprogramming capacities have been
reported for other TFs including Esrrb [33], Klfs
[24,49], Nr5a2 [50], Stat3 [51] and, surprisingly, the germ
cell marker Prdm14 [52], the relative efficiency with
which most of these factors reprogramme EpiSCs with
respect to one another remains unresolved. Similarly to
Esrrb, Klf4 and Klf5, Prdm14 is also a transcriptional
target of Nanog ([33] and Figure 2), and its ability to
reprogramme EpiSC underscores the overlap in charac-
teristics between migratory PGCs and ES cells.
Nanog was previously shown to be required for conver-
sion of EpiSC to ES cells [6]. However, overexpression of
the Nanog target Esrrb bypasses this requirement [33],
raising the possibility that the action of Nanog during
reprogramming may be accounted for by Esrrb. Testing
this notion by attempting to reprogramming Esrrb-null
EpiSCs with Nanog should resolve this issue. Notably,
while Esrrb requires 50Azacytidine to complete repro-
gramming of Nanog/ pre-iPS, reprogramming of
Nanog/ EpiSC is induced efficiently by Esrrb alone.
Possibly EpiSCs have a closer methylation profile to ES
cells than pre-iPS cells. In this regard, Nanog, Oct4 and
Sox2 are expressed in EpiSCs and their promoters are
unmethylated, while the pre-implantation markers Rex-
1, Stella and Fbxo15 have methylated promoters in a
fraction of the EpiSC population [9,25,26]. This differ-
ence between the reprogramming of Nanog/ pre-iPS
and Nanog/ EpiSCs highlights the dual activity that
Nanog exerts during reprogramming, with only the tran-
scriptional upregulation of silent target genes, and not the
reversion of methylation marks being required for EpiSC
reprogramming.Current Opinion in Genetics & Development 2013, 23:504–511
508 Cell reprogrammingIn contrast to human ES cells and EpiSC [2,51], mouse
ES cells self-renew in response to LIF. Nanog was iso-
lated on the basis of its ability to confer LIF independent
self-renewal of mouse ES cells [8], an activity now shown
to require the Nanog target gene Esrrb [33]. Both Esrrb
and the additional direct Nanog target gene Klf4 [33],
can confer LIF independence upon mouse ES cells
[8,18,40], though to varying degrees [33]. It will be
illuminating to determine more fully the epistatic
relationship between TFs required to confer LIF inde-
pendent self-renewal. Klf4 is also elevated in response to
LIF [18] suggesting that the Nanog and the LIF-acti-
vated cascades may converge on a similar set of targetFigure 3
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Current Opinion in Genetics & Development 2013, 23:504–511 genes to impose the pre-implantation PGRN configur-
ation [53]. Supporting this interpretation, LIF/STAT3
signalling is limiting for EpiSC reprogramming [51], but
Nanog expression can bypass this requirement [33,54].
Intriguingly, hyper-activation of LIF signalling can even
override the programmes induced by Activin and FGF in
EpiSC, to promote the generation of chimaera-competent
ES-like cells [55]. In contrast, enforced Nanog expres-
sion in EpiSC lines cannot drive reprogramming without
removal of Activin/FGF [6]. To determine whether
extrinsic signals are dominant over intrinsic determinants
in dictating pluripotent states, it will be important to test
the ability of LIF hyper-activation to reprogrammeCurrent Opinion in Genetics & Development
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reprogramme EpiSC cell lines cultured in N2B27/Acti-
vin/FGF supplemented with LIF.
Applying knowledge towards establishment of
novel human ES cells
As mentioned above, human ES cells can be established
from pre-implantation embryos under conditions used to
establish mouse post-implantation (not pre-implantation)
pluripotent cell lines [2,3]. This raises the question of
whether an equivalent of the mouse pre-implantation
pluripotent state exists in humans. Attempts have been
made to generate human ES cells that possess desirable
traits of mouse ES cells such as clonogenicity [56–58,59].
LIF-dependent human ES cells were obtained using
Oct4/Sox2/Nanog/lin28 [56,60] or using Nanog alongside
Oct4/Sox2/Klf4/myc [57]. LIF-dependent human cells
express pre-implantation markers, though to varying
degrees [57,58,59,60]. Studies using Oct4/Sox2/Klf4/
myc without Nanog found that conversion of human
ES cells to a LIF-dependent state was possible either
in the presence of a compounds that boost Klf4 expression
[58] or by including an Nr5a2 transgene [59]: both of
these TFs can reprogramme EpiSCs [24,50]. With one
notable exception [59], these cells remain dependent on
continued transgene expression [57,58] or signal modu-
lators [56,60]. Perhaps, in these latter cases self-renewal of
converted human ES cells is not robustly sustained
because LIF signalling cannot sufficiently activate the
pre-implantation PGRN which requires further reinforce-
ment from additional TFs.
Perspective
Nanog is crucial in driving establishment of pluripotency
during specification of the pre-implantation epiblast and
for maintenance of the specified PGC population later in
development. By combining in vivo studies with results
generated by in vitro reprogramming of Nanog/ somatic
cells, and the identification of Nanog transcriptional tar-
gets, at least two aspects of Nanog activity have emerged:
first, Nanog regulates expression of other pre-implantation
TFs, and thus stands close to the top of the transcriptional
hierarchy governing the pre-implantation PGRN; second,
Nanog interacts with a number of epigenetic factors
[48,61], targeting them to chromatin and possibly initiat-
ing reversion of repressive marks at silent genes during
establishment of pluripotency (Figure 3). Further investi-
gation of the protein partners and target genes of Nanog
and other PGRN components will provide a fuller un-
derstanding of the relationships between distinct pluripo-
tent cells and will continue to inform studies on
pluripotency in human and other species.
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